The Next Stage of Buprenorphine Care for Opioid Use Disorder
The DOI matches its Crossref record; 58 of the 60 references it cites were found in a registry or an index.
Abstract
Buprenorphine has been used internationally for the treatment of opioid use disorder (OUD) since the 1990s and has been available in the United States for more than a decade. Initial practice recommendations were intentionally conservative, were based on expert opinion, and were influenced by methadone regulations. Since 2003, the American crisis of OUD has dramatically worsened, and much related empirical research has been undertaken. The findings in several important areas conflict with initial clinical practice that is still prevalent. This article reviews research findings in the following 7 areas: location of buprenorphine induction, combining buprenorphine with a benzodiazepine, relapse during buprenorphine treatment, requirements for counseling, uses of drug testing, use of other substances during buprenorphine treatment, and duration of buprenorphine treatment. For each area, evidence for needed updates and modifications in practice is provided. These modifications will facilitate more successful, evidence-based treatment and care for patients with OUD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, while our GBOT model includes psychoeducation components with varying degrees of rigor, psychotherapeutic counseling is not necessary for successful outcomes in B/N treatment.21”
From Implementing Group Visits for Opioid Use Disorder: A Case Series (2020) · cites this paper as [21]
Citations
Cites
Extensional versus intuitive reasoning: The conjunction fallacy in probability judgment.
Tversky, A., & Kahneman, D. (1983) · Psychological Review · doi:10.1037/0033-295x.90.4.293 · Cited by 3,991
Drug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076 · cited 1×
“Buprenorphine, the most commonly used evidencebased treatment of OUD (73, 74) in the United States, is associated with reduced mortality (75, 76).”
BackgroundMedication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic
Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1402780 · Cited by 1,015
D’Onofrio, G., O’Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015) · JAMA · doi:10.1001/jama.2015.3474 · Cited by 910
Tolerating Uncertainty — The Next Medical Revolution?
Simpkin, A. L., & Schwartzstein, R. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1606402 · Cited by 521
Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12600-1 · Cited by 466 · cited 1×
“Early cessation of buprenorphine treatment can have catastrophic effects, including death (21, 64).”
BackgroundDrugs Most Frequently Involved in Drug Overdose Deaths: United States, 2011-2016.
Hedegaard, H. B., Bastian, B. A., Trinidad, J. P., Spencer, M. R. T., & Warner, M. (2018) · PubMed · Cited by 394
Dugosh, K., Abraham, A., Seymour, B., McLoyd, K., Chalk, M., & Festinger, D. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000193 · Cited by 333 · cited 1×
“A systematic review of psychosocial counseling provided with MAT found that “support for the efficacy of delivering concurrent psychosocial interventions was less robust for buprenorphine” (45).”
Cornish, R., Macleod, J., Strang, J., Vickerman, P., & Hickman, M. (2010) · BMJ · doi:10.1136/bmj.c5475 · Cited by 307 · cited 1×
“A 2010 analysis found no reduction in mortality until 20 weeks of treatment; opioid substitution treatment for 12 months or longer was needed to achieve a chance greater than 85% of reducing overall mortality (66).”
BackgroundLong-Term Course of Opioid Addiction
Hser, Y.-I., Evans, E., Grella, C., Ling, W., & Anglin, D. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000052 · Cited by 299
Barriers to Primary Care Physicians Prescribing Buprenorphine
Hutchinson, E., Catlin, M., Andrilla, C. H. A., Baldwin, L.-M., & Rosenblatt, R. A. (2014) · The Annals of Family Medicine · doi:10.1370/afm.1595 · Cited by 289
Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009
Schwartz, R. P., Gryczynski, J., O’Grady, K. E., Sharfstein, J. M., Warren, G., Olsen, Y., Mitchell, S. G., & Jaffe, J. H. (2013) · American Journal of Public Health · doi:10.2105/ajph.2012.301049 · Cited by 276
Lofwall, M. R., & Walsh, S. L. (2014) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000045 · Cited by 248
Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder
Andrilla, C. H. A., Coulthard, C., & Larson, E. H. (2017) · The Annals of Family Medicine · doi:10.1370/afm.2099 · Cited by 204
Fiellin, D. A., Schottenfeld, R. S., Cutter, C. J., Moore, B. A., Barry, D. T., & O’Connor, P. G. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.5302 · Cited by 184
Jones, C. M., Paulozzi, L. J., & Mack, K. A. (2014) · PubMed Central · Cited by 182
Discontinuation of Buprenorphine Maintenance Therapy: Perspectives and Outcomes
Bentzley, B. S., Barth, K. S., Back, S. E., & Book, S. W. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.12.011 · Cited by 176 · cited 1×
“A review of buprenorphine therapy discontinuation found that “rates of relapse to illicit opioid use exceeded 50% in every study” (65).”
BackgroundAbrahamsson, T., Berge, J., Öjehagen, A., & Håkansson, A. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.01.013 · Cited by 169 · cited 1×
“Coprescribing in this study was prevalent: Nearly a third of the sample received prescriptions for both medications (31).”
BackgroundMedication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities
Mojtabai, R., Mauro, C., Wall, M. M., Barry, C. L., & Olfson, M. (2019) · Health Affairs · doi:10.1377/hlthaff.2018.05162 · Cited by 157
Six deaths linked to concomitant use of buprenorphine and benzodiazepines
Reynaud, M., Petit, G., Potard, D., & Courty, P. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.93913859.x · Cited by 151
Kelly, J. F., Wakeman, S. E., & Saitz, R. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.043 · Cited by 130
Visconti, A., Santos, G., Lemos, N. P., Burke, C., & Coffin, P. O. (2015) · Journal of Urban Health · doi:10.1007/s11524-015-9967-y · Cited by 118
Leaving buprenorphine treatment: Patients' reasons for cessation of care
Gryczynski, J., Mitchell, S. G., Jaffe, J. H., O’Grady, K. E., Olsen, Y. K., & Schwartz, R. P. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2013.10.004 · Cited by 118
Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-Based Setting
Alford, D. P., LaBelle, C. T., Richardson, J. M., O’Connell, J. J., Hohl, C. A., Cheng, D. M., & Samet, J. H. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-006-0023-1 · Cited by 104
Nielsen, S., Dietze, P., Lee, N., Dunlop, A., & Taylor, D. (2007) · Addiction · doi:10.1111/j.1360-0443.2006.01731.x · Cited by 93
Schuman-Olivier, Z., Hoeppner, B. B., Weiss, R. D., Borodovsky, J., Shaffer, H. J., & Albanese, M. J. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.04.006 · Cited by 84
Starrels, J. L., Fox, A. D., Kunins, H. V., & Cunningham, C. O. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2165-7 · Cited by 78
Posternak, M. A., & Mueller, T. I. (2001) · The American Journal on Addictions · doi:10.1080/105504901750160484 · Cited by 74
Comparison of opiate-primary treatment seekers with and without alcohol use disorder
Hartzler, B., Donovan, D. M., & Huang, Z. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.05.008 · Cited by 74
Burns, R. M., Pacula, R. L., Bauhoff, S., Gordon, A. J., Hendrikson, H., LESLIE, D. L., & Stein, B. D. (2015) · Substance Abuse · doi:10.1080/08897077.2015.1080208 · Cited by 72
Heikman, P. K., Muhonen, L. H., & Ojanperä, I. A. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1415-y · Cited by 70 · cited 1×
“Although inadequate MAT dosing has been related to increased polysubstance use (62), expecting OUD treatment to affect other substance use is unreasonable (38).”
BackgroundSix Deaths Linked to Misuse of Buprenorphine-Benzodiazepine Combinations
Reynaud, M., Tracqui, A., Petit, G., Potard, D., & Courty, P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.3.447-b · Cited by 68
Medications For Addiction Treatment: Changing Language to Improve Care
Wakeman, S. E. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000275 · Cited by 65
Public sector low threshold office-based buprenorphine treatment: outcomes at year 7
Bhatraju, E. P., Grossman, E., Tofighi, B., McNeely, J., DiRocco, D., Flannery, M., Garment, A., Goldfeld, K., Gourevitch, M. N., & Lee, J. D. (2017) · Addiction Science & Clinical Practice · doi:10.1186/s13722-017-0072-2 · Cited by 65
Home- versus office-based buprenorphine inductions for opioid-dependent patients
Sohler, N. L., Li, X., Kunins, H. V., Sacajiu, G., Giovanniello, A., Whitley, S., & Cunningham, C. O. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2009.08.001 · Cited by 59
Dupouy, J., Palmaro, A., Fatséas, M., Auriacombe, M., Micallef, J., Oustric, S., & Lapeyre-Mestre, M. (2017) · The Annals of Family Medicine · doi:10.1370/afm.2098 · Cited by 59
Unobserved “Home” Induction Onto Buprenorphine
Lee, J. D., Vocci, F., & Fiellin, D. A. (2014) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000059 · Cited by 58
Friedmann, P. D., & Schwartz, R. P. (2012) · Addiction Science & Clinical Practice · doi:10.1186/1940-0640-7-10 · Cited by 51
Cunningham, C. O., Giovanniello, A., Li, X., Kunins, H. V., Roose, R. J., & Sohler, N. L. (2011) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.12.002 · Cited by 51
Buprenorphine treatment for narcotic addiction: not without risks.
Sansone, R. A., & Sansone, L. A. (2015) · Europe PMC (PubMed Central) · Cited by 46
Buprenorphine Treatment Outcomes among Opioid-Dependent Cocaine Users and Non-Users
Cunningham, C. O., Giovanniello, A., Kunins, H. V., Roose, R. J., Fox, A. D., & Sohler, N. (2013) · American Journal on Addictions · doi:10.1111/j.1521-0391.2013.12032.x · Cited by 43
Bakker, A., & Streel, E. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116675508 · Cited by 39
Patient Perspectives Associated with Intended Duration of Buprenorphine Maintenance Therapy
Bentzley, B. S., Barth, K. S., Back, S. E., Aronson, G., & Book, S. W. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.04.002 · Cited by 38
Buprenorphine infrequently found in fatal overdose in New York City
Paone, D., Tuazon, E. D., Stajić, M., Sampson, B. A., Allen, B., Mantha, S., & Kunins, H. V. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.08.007 · Cited by 30
Schwartz, R. P. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000236 · Cited by 30
Friedmann, P. D., & Suzuki, J. (2017) · Addiction Science & Clinical Practice · doi:10.1186/s13722-017-0092-y · Cited by 24
Zhu, Y., Coyle, D. T., Mohamoud, M., Zhou, E. H., Eworuke, E., Dormitzer, C. M., & Staffa, J. A. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.02.019 · Cited by 21
Debate: Are Benzodiazepines Appropriate Treatments for Patients with Substance Use Disorders? Yes
Park, T. W. (2017) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000292 · Cited by 13
Datapoints: Regional Variation in Benzodiazepine Prescribing for Patients on Opioid Agonist Therapy
Park, T. W., Bohnert, A. S. B., Austin, K., Saitz, R., & Pizer, S. D. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300419 · Cited by 11
Crandell, A. E. (2014) · Psychiatric Services · doi:10.1176/appi.ps.650308 · Cited by 10
Mobile Phone Messaging During Unobserved “Home” Induction to Buprenorphine
Tofighi, B., Grossman, E., Sherman, S. E., Nunes, E. V., & Lee, J. D. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000198 · Cited by 10
Buprenorphine MAT as an Imperfect Fix
Mund, B., & Stith, K. (2018) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110518782935 · Cited by 8
Gunderson, E. W. (2011) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31821ee8fe · Cited by 6
Time to Change the Way We Approach Opioid Use Disorder: A Challenge to the Status Quo
Hawk, K. F., & D’Onofrio, G. (2018) · Annals of Internal Medicine · doi:10.7326/m18-2722 · Cited by 4
A Question About the Safety of Buprenorphine/Naloxone and Benzodiazepine Drugs
Howland, R. H. (2015) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20151117-01 · Cited by 3
Ruan, X., Luo, J. J., & Kaye, A. D. (2016) · Drug Research · doi:10.1055/s-0042-119946 · Cited by 2
No proof that buprenorphine treatment requires counseling
Knopf, A. (2017) · Alcoholism & Drug Abuse Weekly · doi:10.1002/adaw.30930 · Cited by 1
Research works printed but not linked: 5
- Sansone RA, 2015, Innov Clin Neurosci, 12, 32
- Warner M, 2016, Natl Vital Stat Rep, 65, 1
- Knopf A, 2017, Alcoholism & Drug Abuse Weekly, 29, 3
- Gabrielson R, 2016, The New York Times, MM34
- Jones CM, 2014, MMWR Morb Mortal Wkly Rep, 63, 881
Cited by
Defining Low-threshold Buprenorphine Treatment
Jakubowski, A., & Fox, A. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000555 · Cited by 203
Krawczyk, N., Williams, A. R., Saloner, B. K., & Cerdá, M. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108329 · Cited by 153
Brown, E., Schutze, M., Taylor, A., Jorgenson, D., McGuire, C. A., Brown, A., Middleton, A., Woodcock, C., LaPres, M., Cohn, L. M., et al. (2021) · JAMA · doi:10.1001/jama.2021.7374 · Cited by 124
The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada
Piske, M., Zhou, H., Min, J. E., Hongdilokkul, N., Pearce, L. A., Homayra, F., Socias, M. E., McGowan, G., & Nosyk, B. (2020) · Addiction · doi:10.1111/add.14947 · Cited by 114
Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings
Taylor, J. L., Johnson, S., Cruz, R., Gray, J. R., Schiff, D. M., & Bagley, S. M. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-06904-4 · Cited by 114
Metadata
- Authors
- Martin, S. A., Chiodo, L. M., Bosse, J. D., & Wilson, A.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- University of Massachusetts Amherst (US)
- CleanSlate Research and Education Foundation, Florence, Massachusetts (A.W.)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2018-11-06
- Volume
- 169
- Issue
- 9
- Pages
- 628-635
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2898142040
- Cited by
- 130
- References
- 60
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 11 · 2023: 10 · 2022: 26 · 2021: 29 · 2020: 17 · 2019: 25 · 2018: 1
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- buprenorphine, opioid use disorder, opioid substitution therapy, relapse, drug testing, polydrug use, treatment duration, evidence-based practice
- MeSH terms
- Benzodiazepines, Buprenorphine, Central Nervous System Agents, Counseling, Drug Therapy, Combination, Humans, Narcotic Antagonists, Opioid-Related Disorders, Recurrence, Substance Abuse Detection, Practice Guidelines as Topic, Patient-Centered Care, Evidence-Based Medicine, Opiate Substitution Treatment, Induction Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.